69
Views
12
CrossRef citations to date
0
Altmetric
Original Research

Investigating the role of pentraxin 3 as a biomarker for bacterial infection in subjects with COPD

, , , , , & show all
Pages 1199-1205 | Published online: 18 Apr 2017

References

  • VestboJHurdSSAgustíAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2013187434736522878278
  • GarveyCRecent updates in chronic obstructive pulmonary diseasePostgrad Med2016128223123826560514
  • BafadhelMMcKennaSTerrySAcute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkersAm J Respir Crit Care Med2011184666267121680942
  • MonsóERuizJRosellABacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brushAm J Respir Crit Care Med19951524131613207551388
  • BanerjeeDKhairOAHoneybourneDImpact of sputum bacteria on airway inflammation and health status in clinical stable COPDEur Respir J200423568569115176680
  • SethiSMurphyTFInfection in the pathogenesis and course of chronic obstructive pulmonary diseaseN Engl J Med2008359222355236519038881
  • PapiABellettatoCBraccioniFInfections and airway inflammation in chronic obstructive pulmonary disease severe exacerbationsAm J Respir Crit Care Med2006173101114112116484677
  • BhowmikASeemungalTSapsfordRWedzichaJRelation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbationsThorax200055211412010639527
  • MiravitllesMMarínAMonsóEColour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary diseaseRespir Res2010111585820470372
  • RosellAMonsóESolerNMicrobiologic determinants of exacerbation in chronic obstructive pulmonary diseaseArch Int Med2005165889189715851640
  • National Clinical Guideline Centre2010Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary careLondonNational Clinical Guideline Centre Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/EnglishAccessed September 1, 2015
  • Global Strategy for diagnosis m, and prevention of COPD Available from: www.goldcopd.orgAccessed March 14, 2016
  • Recommendations of the Clinical Subcommittee of the Medical/Scientific Advisory Committee of the Canadian Cystic Fibrosis FoundationMicrobiological processing of respiratory specimens from patients with cystic fibrosisCan J Infect Dis19934316616922346442
  • ErkanLUzunOFindikSKatarDSanicAAticiAGRole of bacteria in acute exacerbations of chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20083346346718990975
  • BerkowitzFEAntibiotic resistance in bacteriaSouth Med J19958887978047631202
  • BalharaJKoussihLZhangJGounniASPentraxin 3: an immuno-regulator in the lungsFront Immunol2013412723755050
  • KunesPHolubcovaZKolackovaMKrejsekJPentraxin 3(PTX 3): an endogenous modulator of the inflammatory responseMediators Inflamm2012201292051722577258
  • SoaresACSouzaDGPinhoVDual function of the long pentraxin PTX3 in resistance against pulmonary infection with Klebsiella pneumoniae in transgenic miceMicrobes Infect2006851321132916697676
  • VänskäMKoivulaIHämäläinenSHigh pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patientsHaematologica20119691385138921880642
  • Bastrup-BirkSSkjoedtMOMunthe-FogLStromJJMaYJGarredPPentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndromePLoS One201389e7311924039869
  • HuttunenRHurmeMAittoniemiJHigh plasma level of long pentraxin 3 (PTX3) is associated with fatal disease in bacteremic patients: a prospective cohort studyPLoS One201163e1765321423699
  • HollanIBottazziBCuccovilloIIncreased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic diseaseArthritis Care Res (Hoboken)201062337838520391484
  • AnthonisenNRManfredaJWarrenCPWHershfieldESHardingGKMNelsonNAAntibiotic therapy in exacerbations of chronic obstructive pulmonary diseaseAnn Int Med198710621962043492164
  • Chronic obstructive pulmonary disease2016 Available from: https://www.nice.org.uk/guidance/Accessed November 1, 2015
  • WeatherallMMarshSShirtcliffePWilliamsMTraversJBeasleyRQuality of life measured by the St George’s respiratory questionnaire and spirometryEur Respir J20093351025103019164350
  • MRCMedical Research Council Dyspnoea scale/Breathlessness scale [webpage on the Internet] Available from: https://www.mrc.ac.uk/research/facilities-and-resources-for-researchers/mrc-scales/mrc-dyspnoea-scale-mrc-breathlessness-scale/Accessed November 1, 2015
  • ChauvinARupleyLMeyersKJohnsonKEasonJOutcomes in cardiopulmonary physical therapy: chronic respiratory disease questionnaire (CRQ)Cardiopulm Phys Ther J2008192616720467499
  • BrightlingCEMonterioWGreenRHInduced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatabilityRespir Med20019512999100211778799
  • PizzichiniEPizzichiniMMEfthimiadisAHargreaveFEDolovichJMeasurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contaminationEur Respir J199696117411808804934
  • PyeAStockleyRAHillSLSimple method for quantifying viable bacterial numbers in sputumJ Clin Pathol19954887197247560197
  • WagenerAHde NijsSBLutterRExternal validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthmaThorax201570211512025422384
  • RabeKFHurdSAnzuetoAGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2007176653255517507545
  • BottazziBDoniAGarlandaCMantovaniAAn integrated view of humoral innate immunity: pentraxins as a paradigmAnn Rev Immunol201028115718319968561
  • KurtOKTosunMKurtEBTalayFPentraxin 3 as a novel biomarker of inflammation in chronic obstructive pulmonary diseaseInflammation2015381899325303877
  • SchwingelFLPizzichiniEKlevestonTPentraxin 3 sputum levels differ in patients with chronic obstructive pulmonary disease vs asthmaAnn Allergy Asthma Immunol2015115648548926508705
  • Van PottelbergeGRBrackeKRPauwelsNSVermassenFEJoosGFBrusselleGGCOPD is associated with reduced pulmonary interstitial expression of pentraxin-3Eur Respir J201239483083821920889
  • LiuSQuXLiuFWangCPentraxin 3 as a prognostic biomarker in patients with systemic inflammation or infectionMediators Inflamm2014201442142925530683
  • MantovaniACassatellaMACostantiniCJaillonSNeutrophils in the activation and regulation of innate and adaptive immunityNat Rev Immunol201111851953121785456
  • BafadhelMHaldarKBarkerBAirway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung functionInt J Chron Obstruct Pulmon Dis2015101075108326089657
  • BarkerBLHaldarKPatelHAssociation between pathogens detected using quantitative polymerase chain reaction with airway inflammation in COPD at stable state and exacerbationsChest201414714655
  • KleinDQuantification using real-time PCR technology: applications and limitationsTrends Mol Med20028625726012067606
  • NockerASossa-FernandezPBurrMDCamperAKUse of propidium monoazide for live/dead distinction in microbial ecologyAppl Environl Microbiol2007731651115117